APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.
12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners
13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.
Zolmitripan Oral Dispersible Film (ODF) strip uses the proprietary RapidFilm® technology (for the European
development) and the PharmFilm® technology (for the US market) which are a novel, non-mucoadhesive, fast
dissolving oral dosage that provides:
> Quick onset of action comparable to novel oral formulations (ODTs)
> T-max plasma concentration achieved in 1.5 hr. vs. 4hr. with the nasal spray.
> More cost effective and with better compliance compared to nasal sprays that reports a high incidence of side effects
like bad taste (20-25%), nose and throat discomfort (more than 6%) and occurrence of aftertaste (possible trigger of
nausea)
> Better compliance compared to other oral formulations, not requiring any intake of water or pills (possible trigger of
nausea)
